2021年10月11日讯 /生物谷BIOON/ --安进（Amgen）近日宣布，美国食品和药物管理局（FDA）已批准Repatha（瑞百安®，通用名：通用名 ...

Biotech giant Amgen (NASDAQ: AMGN) announced yesterday that the FDA has approved the Repatha Pushtronex system. This new system is a pre-filled, on-body medical device that allows for monthly, ...

Amgen Inc.AMGN announced that the FDA has approved a new, monthly single-dose administration option for its PCSK9 inhibitor, Repatha. The Repatha Pushtronex system, an on-body infusor with a prefilled ...

Repatha pushtronex The Pushtronex system is an on-body infusor with a prefilled cartridge intended for once-monthly administration. Amgen announced that the Food and Drug Administration (FDA) has ...

Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...

BETHESDA, MD — The US Food and Drug Administration (FDA) has approved the evolocumab (Repatha, Amgen) Pushtronex system, the first once-monthly delivery option for a proprotein convertase subtilisin ...

Amgen has won FDA approval for a new device that allows for monthly dosing of its cholesterol-busting drug Repatha. Is it a game-changing innovation in its fight against Regeneron Pharmaceuticals and ...

Repatha may help reduce the risk of heart attack, stroke, and heart surgery for adults with heart disease. It might also lower low-density lipoprotein (LDL) cholesterol in adults and children with ...

Repatha reduced the risk of heart attack by 27%, the risk of stroke by 21% and the risk of coronary revascularization by 22%. Amgen announced that the Food and Drug Administration (FDA) has approved ...

EXTON, Pa., July 11, 2016 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the U.S. Food ...

Please provide your email address to receive an email when new articles are posted on . The product is indicated as an adjunct therapy for adults with heterozygous familial hypercholesterolemia or ...